Viewing Study NCT07047560


Ignite Creation Date: 2025-12-25 @ 2:15 AM
Ignite Modification Date: 2025-12-26 @ 12:45 AM
Study NCT ID: NCT07047560
Status: RECRUITING
Last Update Posted: 2025-07-02
First Post: 2025-06-24
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module